Skip to main content
Clinical Trials/NCT04065997
NCT04065997
Terminated
Not Applicable

Apogee International

Medtronic Cardiac Rhythm and Heart Failure31 sites in 17 countries147 target enrollmentSeptember 6, 2019

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Chronic Heart Failure
Sponsor
Medtronic Cardiac Rhythm and Heart Failure
Enrollment
147
Locations
31
Primary Endpoint
Major adverse events
Status
Terminated
Last Updated
4 years ago

Overview

Brief Summary

Medtronic is sponsoring the Apogee International registry to further confirm safety and efficacy of the HVAD™ System when used as intended, in "real world" clinical practice and to enhance scientific understanding of the implant procedure, optimized blood pressure management, anticoagulation/ antiplatelet therapies, logfile analysis and acoustic spectrum analysis in patients receiving a Medtronic HeartWare™ HVAD™ for bridge to transplant and destination therapy indications.

Detailed Description

Apogee International is a prospective, non-interventional, post-market, multi-site registry, conducted within Medtronic's Product Surveillance Registry (PSR) Platform. Enrollment into Apogee International will be comprised of newly implanted, commercial use patients with the HeartWare Ventricular Assist Device System (HVAD System). Sites selected to participate are expected to collect data in at least one of these five modules: 1. Logfile Download; 2. Anti-coagulation / Anti-platelet Management; 3. Blood Pressure (BP) Management; 4. Acoustic Spectrum Analysis; 5. Infection Control

Registry
clinicaltrials.gov
Start Date
September 6, 2019
End Date
July 26, 2021
Last Updated
4 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Medtronic Cardiac Rhythm and Heart Failure
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patient or legally authorized representative provides written authorization and/or consent per institution and geographical requirements;
  • Enrollment into Apogee International will be comprised of newly enrolled, commercial use patients with the HeartWare HVAD System;
  • Patient is consented prior to the HVAD implant procedure.

Exclusion Criteria

  • Patient who is, or is expected to be inaccessible for follow-up;
  • Participation is excluded by local law;
  • Patient is currently enrolled or plans to enroll in concurrent drug/device study that may confound the PSR results.

Outcomes

Primary Outcomes

Major adverse events

Time Frame: Implant to 12 months

Major adverse events are defined to be occurrence of major infection, major bleeding, device malfunction, stroke or death.

Study Sites (31)

Loading locations...

Similar Trials